The data support the value of standard fecal examinations in human immunodeficiency virus-infected patients, even in the absence of diarrhea, since these examinations easily can be performed, with low costs, and frequently disclose treatable conditions.
Infection with drug-resistant human immunodeficiency virus type 1 (HIV-1) has been documented in all countries that have surveyed for it and may result in an unfavorable response to therapy. The prevalence and characteristics of individuals with transmitted resistance to antiretroviral drugs have been scarcely described in Brazil. We performed antiretroviral resistance testing prior to initiation of therapy in 400 subjects enrolled from 20 centers in 13 Brazilian cities between March and September 2007. Genotyping was conducted using PCR-amplified HIV pol products by automated sequencing, and genotype interpretation was done according to the IAS-USA consensus. Of 400 eligible participants, 387 (95.8%) were successfully tested. Seven percent of antiretroviral-naive patients carried viruses with one or more major mutation associated with drug resistance. The prevalence of these mutations was 1.0% for protease inhibitors, 4.4% for nonnucleoside reverse transcriptase inhibitors, and 1.3% for nucleoside reverse transcriptase inhibitors. The frequency of multidrug resistance among the resistant strains was 13.6%. Among subjects infected with drug-resistant virus, the majority were infected with subtype B viruses (91%). Subjects from the city of São Paulo had higher transmitted resistance mutations compared to the rest of the country. Reporting a partner taking antiretroviral medications was associated with a higher chance of harboring HIV variants with major drug resistance mutations [odds ratio = 2.57 (95% confidence interval, 1.07-6.16); p = 0.014]. Resistance testing in drug-naive individuals identified 7% of subjects with mutations associated with reduced susceptibility to antiretroviral drugs. Continued surveillance of drug-resistant HIV-1 in Brazil is warranted when guidelines for HIV prophylaxis and treatment are updated. Resistance testing among drug-naive patients prior to treatment initiation should be considered, mainly directed at subjects whose partners are already on antiretroviral therapy.
Amongst the causes of diarrhea in developing countries, those of a parasitic origin are prominent in patients with AIDS.Opportunistic infections caused by intestinal parasites also vary according to the geographical area and the endemic levels in each location.The progressive decline of immunological and mucous defense mechanisms predisposes patients to early, intermediary and late gastrointestinal manifestations of HIV infection. 6 At later stages of the disease, the alterations in non-specific defense mechanisms in the production of Ig A and the reduction in local immune cell response also progress, thus increasing the susceptibility to a number of intestinal opportunistic pathogens, among which Cryptosporidium parvum, Isospora belli and Microsporidia species are the most prominent. 7After the emergence of AIDS, these parasites, until then known solely in veterinary medicine, were no longer considered as commensal organisms and are nowadays recognized as opportunistic pathogens common to these patients. Infections by these agents constitute a major secondary aggravating factor of the disease, often responsible for worsening the general health conditions, due to manifestations of diarrhea which are difficult to control, sometimes resulting in the death of the patient. CRYPTOSPORIDIASISCryptosporidiasis, a disease caused by an intracellular protozoan named Cryptosporidium sp, was described for the first time in 1907 by Tyzzer. This parasite was considered a commensal up to 1975, when it was identified as the cause of diarrhea in animals. 8 The first manifestation of cryptosporidiasis was reported by Nine et al. in 1976, and the disease became a major concern when the notification of the first 21 patients was given, 14 of whom died of chronic diarrhea caused by Cryptosporidium sp infection. 9 It is worth noting that outbreaks of epidemic linked to contaminated water are of extreme importance for the dissemination of this parasite such as the 1993 Milwaukee (USA) cryptosporidiasis outbreak, in which 403,000 human cases were reported, thereby becoming a relevant public health concern.10-12 After this outbreak, it was recommended that immunocompromised patients should be extremely careful with water, foodstuffs and contact with animals.Cryptosporidiasis is distributed over all continents. In Haiti and the African continent the prevalence is 50%, 13 while in the USA it ranges from 3 to 4%.14 In Brazil, due to the continental size of the country, the rates of incidence vary with the location. In the city of São Paulo, for instance, reports have referred to levels around 12.1 to 24.44%. [15][16][17] However, the latest epidemiological report on Brazil, dated February 1998, shows a cryptosporidiasis rate of only 3.5%. 18Cryptosporidiasis in AIDS patients usually causes chronic, bulky and intermittent diarrhea, with liquid non-bloody stools, accompanied by pain and abdominal colic, and a noticeable loss of weight can be observed. 8Asymptomatic cases are rarely described, occurring mostly in developing countries with pati...
The results showed undesired nutritional and metabolic conditions among patients on HAART associated with CD. It is necessary to manage health intervention programs for PLHA in order to control cardiovascular risk factors before final outcomes.
Our findings suggest an imbalance between endothelial progenitor cells mobilization and endothelial apoptosis. The alteration in the turnover of endothelial cells may contribute to cardiovascular events in HIV-infected patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.